ENTRY-DM: Interdisciplinary doctoral training on oligonucleotide based therapies for myotonic dystrophy
Rare diseases, though individually infrequent, collectively pose important challenges for patients, clinicians and researchers in terms of d...
2024-06-28 - 2029-02-28 | Financiado
2024-06-28 - 2029-02-28 | Financiado
DREAMS: Drug REpurposing with Artificial intelligence for Muscular disorderS
CENTRE DETUDE DES CELLULES SOUCHES
tramitó un
HORIZON EUROPE:
HORIZON-HLTH-2022-DISEASE-06-two-stage
According to World Health Organization, to date, fewer than 6% of rare diseases (RDs) have an approved treatment option. In the light of thi...
2023-10-08 - 2028-10-31 | Financiado
2023-10-08 - 2028-10-31 | Financiado
* No se disponen de datos de la empresa actual.